KPV vs Thymosin Alpha-1
Specialty
KPV
C-terminal tripeptide fragment of α-MSH studied for anti-inflammatory signaling without melanocortin receptor pigmentation effects.
Specialty
Thymosin Alpha-1
28-amino-acid thymic peptide studied for Toll-like receptor signaling and T-cell maturation.
Side by side
| Dimension | KPV | Thymosin Alpha-1 |
|---|---|---|
| Molecular weight A 9.1× difference in mass — these are not comparable on a milligram-for-milligram basis. | 342.44 g/mol | 3108.3 g/mol |
| Size class | small molecule / short peptide | mid-length peptide |
| CAS number | 67727-97-3 | 62304-98-7 |
| Research area | specialty | specialty |
| Sequence | Lys-Pro-Val | Not published as a linear sequence |
| Available sizes | 10mg | 10mg |
| Entry price | $49 | $59 |
| Cost per mg | $4.90 | $5.90 |
Mechanism
KPV
KPV is the C-terminal tripeptide (residues 11-13) of alpha-melanocyte-stimulating hormone. Its research interest stems from retaining anti-inflammatory activity attributed to the parent hormone while lacking the melanocortin receptor binding responsible for pigmentation effects — making it a useful tool for separating those two activities. Work has examined NF-κB pathway inhibition in intestinal epithelial models.
Thymosin Alpha-1
Thymosin alpha-1 is a 28-amino-acid N-terminally acetylated peptide originally isolated from thymic tissue. It is among the better-characterized immunomodulatory peptides, with published mechanism centering on TLR2 and TLR9 signaling in dendritic cells and downstream effects on T-cell differentiation. Unlike much of this catalog, it has an established clinical literature under the name thymalfasin.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
KPV
Evidence base: small but mechanistically coherent in the intestinal context, where PepT1-mediated uptake gives a defined transport route. Antimicrobial findings are thinner. Search results require filtering, since the sequence occurs incidentally in unrelated proteins.
Full research reference →Thymosin Alpha-1
Evidence base: the largest and highest-quality in this catalogue after the incretin compounds. Multiple approved indications and a 2025 randomised phase 3 sepsis trial. The modulatory mechanism is context-dependent and correspondingly harder to interpret than a simple agonist relationship.
Full research reference →Research applications
KPV
- NF-κB signaling pathway inhibition assays
- Intestinal epithelial inflammation models
- PepT1 transporter-mediated uptake studies
- Cytokine expression profiling
Thymosin Alpha-1
- TLR2 and TLR9 signaling assays in dendritic cell culture
- T-cell maturation and differentiation studies
- Cytokine profiling (IL-2, IFN-γ) in immune models
- Vaccine adjuvant research
Common questions
What is the difference between KPV and Thymosin Alpha-1?
KPV is c-terminal tripeptide fragment of α-MSH studied for anti-inflammatory signaling without melanocortin receptor pigmentation effects. Thymosin Alpha-1 is 28-amino-acid thymic peptide studied for Toll-like receptor signaling and T-cell maturation. They differ in molecular weight (342.44 vs 3108.3 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, KPV or Thymosin Alpha-1?
KPV is lower at approximately $4.90 per milligram at its best tier, against $5.90 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can KPV and Thymosin Alpha-1 be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should KPV and Thymosin Alpha-1 be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days. For Thymosin Alpha-1: Store lyophilized at -20°C protected from light. Reconstituted at 2-8°C for up to 30 days.
Which has the stronger evidence base?
KPV — Evidence base: small but mechanistically coherent in the intestinal context, where PepT1-mediated uptake gives a defined transport route. Antimicrobial findings are thinner. Search results require filtering, since the sequence occurs incidentally in unrelated proteins. Thymosin Alpha-1 — Evidence base: the largest and highest-quality in this catalogue after the incretin compounds. Multiple approved indications and a 2025 randomised phase 3 sepsis trial. The modulatory mechanism is context-dependent and correspondingly harder to interpret than a simple agonist relationship.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.